Shunmay Yeung is a paediatrician specisalising in infectious disease and global health with a background in health economics and operational research.

She is the lead investigator for PACES (Proactive Case Detection and Community Particiation for the elimination of drug resistant malaria study) in Cambodia, as part of the Tracking Resistance to Artemisinins Collaboration (TRAC), a large programme of research led by the Mahidol-Oxford Research Unit in Bangkok funded by DfID.  She is also a workpackage lead for the PERFORM study, an ambitious EU Horizon 2020 project co-ordinated by Prof Mike Levin of Imperial College which involves 12 sites in 8 countries in Europe,the Gambia and Nepal.  PERFORM aims to develop and validate new "-omics" based diagnostic technologies for differentiating bacterial from viral infections in children in order to improve the management of acute febrile illness and reduce unnecesary antimicrobial use.  The workpackage led by Shunmay aims to describe and compare the management of children with fever and to assess the potential cost-effectivness of new diagnostics. 

She co-leads the Centre for Maternal, Adolescent, Reproductive and Child Health - Child Theme, and is active clinically as a consultant in Paediatric Infectious Disease at St Mary's Imperial College Hospital, London.  

She did her clinical training in London and worked as a government medical officer in a district hospital in rural KwaZulu/Natal in South Africa where she also undertook clinical research on HIV in children.  In October 2014 she was deployed as a clinical advisor to Sierra Leone with Save the Children in order to help in the set up of the Ebola Treatment Centre in Kerrytown.  She subsequently returned to Sierra Leone to supervise research on the managment and outcome of children admitted to Ebola Holding Units during the crisis. 

Her PhD was on antimalarial drug resistance and drug policy and was undertaken in Southeast Asia, under the supervision of Professors Sir Nicholas White and Anne Mills, with funding from the Wellcome Trust.  It employed economic and epidemiological modeling and field studies on the access to malaria diagnosis and treatment.  She continues to call upon this experience to help bridge between research, policy and practice.  

She was Deputy Director of the ACT consortium and the co-ordinating investigator for the Artemisinin  Resistance Confirmation, Characterization and Containment (ARC3) consortium, both funded by the BMGF. She has worked for WHO Geneva as as a Medical Officer in the Global Malaria Programme and sits on a number of expert committees and advisory boards.